Michelson Diagnostics Ltd., an Orpington, UK-based developer of medical equipment and scanner solutions, has raised £1.7m from Octopus Investments.
Founded by CEO Jon Holmes in 2006, the company has developed a laser scanning technology that is designed to image skin and other surface tissue at a higher resolution than ever before. Its first product, the VivoSight scanner, is aimed to revolutionize the market for the non-invasive diagnosis and treatment of non-melanoma skin cancer (NMSC).
It has already won CE and Food and Drug Administration (FDA) regulatory clearance for clinical use in Europe and the USA, and is now being trialled by leading skin cancer specialists at their clinics.
The investment will fund the manufacture and placement of VivoSight scanners and will support the growth of the sales infrastructure in the UK and USA.